From May 1, 2023 to July 31, 2023, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 1,883,346 shares, representing 10.34% for $5.63 million under the buyback announced on February 2, 2023.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.2 USD | +3.77% | +3.29% | +1.85% |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+1.85% | 17.92M | |
+34.11% | 664B | |
+29.29% | 567B | |
-6.95% | 354B | |
+19.56% | 330B | |
+4.50% | 286B | |
+13.57% | 234B | |
+5.31% | 199B | |
-9.69% | 196B | |
-4.64% | 148B |
- Stock Market
- Equities
- PMCB Stock
- News PharmaCyte Biotech, Inc.
- Tranche Update on PharmaCyte Biotech, Inc.'s Equity Buyback Plan announced on February 2, 2023.